Elisabeth Boucher
Associate Director, Analytical Development Tessera Therapeutics
Seminars
Wednesday 25th February 2026
Roundtable Discussion: Translating Complex mRNA Characterization Assays into QC-Ready Strategies to Reduce Downtime between Teams
9:30 am
- How to adapt AD assays into validated QC workflows to ensure reproducibility across sites and manufacturing scales
- How to overcome challenges of assay transfer, variability, and lack of reference standards to safeguard consistency and compliance
- How to embed standardized characterization workflows to support smoother regulatory submissions, tech transfer and global comparability
Wednesday 25th February 2026
Advancing Impurity and Residual Analysis to Strengthen mRNA Product Quality and QC Readiness
3:30 pm
- Developing and optimizing assays to detect and quantify critical impurities and residuals including dsRNA, proteins, and DNA in mRNA therapeutics
- Translating analytical rigor from development to QC to ensure reproducibility, compliance, and regulatory acceptance
